Medicus Pharma Ltd. Common Stock (MDCX) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Medicus Pharma Ltd. Common Stock (MDCX) Earnings Overview
As of June 22, 2026, Medicus Pharma Ltd. Common Stock (MDCX) reported trailing twelve-month net income of -$37M, reflecting -69.0% year-over-year growth. The company earned $-1.25 per diluted share over the past four quarters.
Looking at the long-term picture, MDCX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2022.
Medicus Pharma Ltd. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SIGA ($20M net income, 24.6% margin), NUVB (-$146M net income, -325.3% margin), IMVT (-$506M net income), MDCX has comparable earnings metrics. Compare MDCX vs SIGA →
MDCX Earnings vs Peers
Earnings metrics vs comparable public companies
MDCX Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$25M | -127.4% | -$18M | $-1.96 | - | - |
| 2024 | -$11M | -109.9% | -$11M | $-1.16 | - | - |
| 2023 | -$5M | -214.0% | -$5M | $-1.06 | - | - |
| 2022 | -$2M | +17.7% | $-978,416 | $-0.21 | - | - |
| 2021 | -$2M | - | -$1M | $-0.26 | - | - |
Download Data
Export MDCX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MDCX — Frequently Asked Questions
Quick answers to the most common questions about buying MDCX stock.
What is MDCX earnings per share (EPS)?
MDCX trailing twelve-month (TTM) diluted EPS is $-1.25, reflecting -69.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Medicus Pharma Ltd. Common Stock's net income?
Medicus Pharma Ltd. Common Stock (MDCX) trailing twelve-month net income is $-37M as of 2025. Earnings declined -69.0% year-over-year.
Is MDCX profitable?
MDCX is not currently profitable on a TTM basis, reporting a net loss of $-37M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MDCX's earnings growth rate?
MDCX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are MDCX's profit margins?
Medicus Pharma Ltd. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -1599.4%.
Is MDCX growing earnings?
MDCX earnings are declining — EPS fell -69.0% year-over-year. TTM net income dropped to $-37M. This contrasts with the 5-year CAGR of N/A.
What was MDCX's best earnings year?
Medicus Pharma Ltd. Common Stock's highest annual net income on record is $-2M, achieved in fiscal year 2022. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were MDCX's earnings last quarter?
MDCX's most recent reported quarter was Q1 2026. Net income was $-7M with diluted EPS of $-0.22. For a full breakdown of all quarters, see the quarterly earnings table on this page.